RNTX · NASDAQ
Rein Therapeutics (RNTX) Stock Price & Fundamentals
Rein Therapeutics (RNTX) closed at $632.32 on Oct 9, 2026, down 0.89% from the previous close of $637.97.
Share price, past year
1Y +12.36%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $632.32 |
| Sep 30, 2026 | $627.98 |
| Aug 31, 2026 | $632.30 |
| Jul 31, 2026 | $594.91 |
| Jun 30, 2026 | $570.26 |
| May 29, 2026 | $561.73 |
| Apr 30, 2026 | $561.77 |
| Mar 31, 2026 | $504.22 |
| Feb 27, 2026 | $544.52 |
| Jan 30, 2026 | $552.48 |
| Dec 31, 2025 | $571.34 |
| Nov 28, 2025 | $576.04 |
| Oct 31, 2025 | $560.55 |
Key statistics
- Market cap
- $54.23B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.72
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$49.76M
- Shares outstanding
- 85.8M
- Dividend yield
- —
- 52-week range
- $503.10 – $644.48
Rein Therapeutics's market cap is $54.23B, based on a share price of $632.32 and 85.8M shares outstanding as of Jun 30, 2026.
Financials
Rein Therapeutics reported revenue of $0.00 for fiscal 2025.
Rein Therapeutics reported a net loss of $49.87M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$49.87M | — | −$1.96 | — |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$62.88M | — | −$3.51 | — |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$15.73M | — | −$3.42 | — |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$27.33M | — | −$6.02 | — |
| FY2021ended Dec 31, 2021 | $0.00 | — | −$26.16M | — | −$117.80 | −$23.91M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$27.33M | — | −$12.20 | −$20.48M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$29.37M | — | −$24.00 | −$26.63M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$31.55M | — | −$42.80 | −$32.35M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$22.60M | — | −$60.80 | −$20.67M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$18.12M | — | −$847.00 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$6.38M | −$0.10 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$5.84M | −$0.19 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$31.97M | −$1.22 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$5.58M | −$0.21 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$6.82M | −$0.28 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$5.50M | −$0.25 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$40.98M | −$1.93 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$5.85M | −$0.27 |
Company profile
- Name
- Rein Therapeutics, Inc.
- Ticker
- RNTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 12407 N. Mopac Expy., Suite 250 #390, Austin, TX 78758
- Fiscal year ends
- December
- SEC CIK
- 0001420565
Recent SEC filings
- Sep 4, 2026
- Aug 27, 2026
- Aug 14, 2026
- Jul 21, 2026
- May 15, 2026
- May 4, 2026
- Apr 27, 2026
- Mar 26, 2026
Frequently asked questions
What is Rein Therapeutics's stock price?
Rein Therapeutics (RNTX) closed at $632.32 on Oct 9, 2026, down 0.89% from the previous close of $637.97.
What is Rein Therapeutics's market cap?
Rein Therapeutics's market cap is $54.23B, based on a share price of $632.32 and 85.8M shares outstanding as of Jun 30, 2026.
How much revenue does Rein Therapeutics make?
Rein Therapeutics reported revenue of $0.00 for fiscal 2025.
Does Rein Therapeutics pay a dividend?
Yes. Rein Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Rein Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures